Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...117118119120121122123124125126127...401402»
  • ||||||||||  Trial primary completion date:  Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis (clinicaltrials.gov) -  May 8, 2023   
    P=N/A,  N=44, Not yet recruiting, 
    Sarcopenia, defined as a low CT-measured SMG, provides extra value in predicting mortality in older PPU patients. Trial primary completion date: Dec 2023 --> Aug 2024
  • ||||||||||  Journal:  Physical activity in sarcopenia: rehabilitation approaches in prevention and treatment of age-related muscle disorders (Pubmed Central) -  May 8, 2023   
    Furthermore, the pathogenetic relationship between the lack of physical activity and muscle dysfunction in elderly people is broached, including in particular the role of myostatin, interleukin-6, somatotropin and insulin resistance. The article represents possibilities of impact of aerobic, strength and neuromuscular physical exercises on prevention and correction of sarcopenic changes in different age groups based on the analysis of current clinical studies.
  • ||||||||||  Review, Journal:  The crosstalk between BAT thermogenesis and skeletal muscle dysfunction. (Pubmed Central) -  May 8, 2023   
    Moreover, manipulation of BAT may be an attractive approach for the treatment of muscle weakness by correcting metabolic deficits. Therefore, exploring BAT as a potential treatment for sarcopenia could be a promising avenue for future research.
  • ||||||||||  Journal:  Intermittent fasting interventions to leverage metabolic and circadian mechanisms for cancer treatment and supportive care outcomes. (Pubmed Central) -  May 8, 2023   
    An outstanding concern regarding the use of intermittent fasting among cancer patients is that fasting often results in caloric restriction, which can put patients already prone to malnutrition, cachexia, or sarcopenia at risk. Although clinical trials do not yet provide sufficient data to support the general use of intermittent fasting in clinical practice, this summary may be useful for patients, caregivers, and clinicians who are exploring intermittent fasting as part of their cancer journey for clinical outcomes and symptom management.
  • ||||||||||  Review, Journal:  Cirrhosis and Sarcopenia. (Pubmed Central) -  May 8, 2023   
    Additional studies have demonstrated reversal and improved survival in sarcopenic patients who have undergone transjugular intrahepatic portosystemic shunt placement. Thus, accounting for sarcopenia can help risk stratify patients prior to interventional procedures to allow for better outcomes and improved survival.
  • ||||||||||  methotrexate / Generic mfg.
    Clinical data, Retrospective data, Review, Journal:  Risk Factors and Clinical Outcomes Associated With Sarcopenia in Rheumatoid Arthritis: A Systematic Review and Meta-analysis. (Pubmed Central) -  May 7, 2023   
    Factors associated with sarcopenia included higher 28-joint Disease Activity Scale scores (+0.39; 95% confidence interval, +0.02 to +0.77) and baseline methotrexate use (odds ratio, 0.70; 95% confidence interval, 0.51-0.97)...Sarcopenia is prevalent in RA, and it may be associated with higher RA disease activity, lower bone mineral density, and increased falls and fractures. Therefore, early screening of sarcopenia in RA patients is important to incorporate into clinical rheumatology practice.
  • ||||||||||  Review, Journal:  Role of the Osteocyte in Musculoskeletal Disease. (Pubmed Central) -  May 7, 2023   
    Bone and muscle not only communicate mechanically but also biochemically. Osteocyte-derived factors appear to contribute to the pathogenesis of muscle disease and could be used as a cellular target for new therapeutic approaches.
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Sauna: Passive Heat Treatment and Skeletal Muscle Reconditioning Older Adults (clinicaltrials.gov) -  May 6, 2023   
    P=N/A,  N=14, Completed, 
    Diagnostic and intervention packages targeting such patients should be developed and implemented in high-risk settings. Not yet recruiting --> Completed | Trial completion date: Jul 2023 --> Dec 2022 | Trial primary completion date: Apr 2023 --> Dec 2022
  • ||||||||||  Journal, IO biomarker:  Identification of novel pathways and immune profiles related to sarcopenia. (Pubmed Central) -  May 4, 2023   
    The upregulation of SLURP1 and LCE1C was associated with a worse prognosis and weaker immune profile. This study provides new insight into sarcopenia's cellular and immunological prospects and evaluates the age and sarcopenia-related modifications of skeletal muscle.
  • ||||||||||  SARCOPENIA AS A PREDICTOR OF MORTALITY IN KIDNEY TRANSPLANT RECIPIENTS (Focussed Oral Room 7) -  May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_2088;    
    This study provides new insight into sarcopenia's cellular and immunological prospects and evaluates the age and sarcopenia-related modifications of skeletal muscle. Sarcopenia was a significant predictor of mortality in kidney transplant recipients.
  • ||||||||||  Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
    THE NUTRITIONAL ASSESSMENT TOOLS TO IDENTIFY PATIENTS AT INCREASED SARCOPENIA RISK (Focussed Oral Room 7) -  May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1670;    
    The NRI-JH and GNRI were significantly associated with risk of sarcopenia. The NRI-JH demonstrated a stronger association with the risk of sarcopenia compared to the GNRI.
  • ||||||||||  OSTEOSARCOPENIA AMONG PATIENTS UNDERGOING HEMODIALYSIS IS RELATED WITH MORTALITY (Focussed Oral Room 10) -  May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1596;    
    The NRI-JH demonstrated a stronger association with the risk of sarcopenia compared to the GNRI. Patients undergoing hemodialysis had a high incidence of sar copenia and osteosarcopenia, muscle mass and strength showed a significant association with BMD, and osteosarcopenia might have a powerful impact on mortality in those patients.
  • ||||||||||  IMPACT OF HEART FUNCTION ON ELDERLY INCIDENT HEMODIALYSIS PATIENTS (Focussed Oral Room 10) -  May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1409;    
    Decreased heart function and presence of arrhythmia have negative impact on all-cause mortality of overall period, but not on 6-month all-cause mortality in elderly patients on incident HD. Therefore, evaluation of the heart function and detection of arrhythmia in elderly patients who start HD and providing the appropriate treatment to these patients would be helpful for improving the prognosis.
  • ||||||||||  Journal:  Sarcopenia and Ageing. (Pubmed Central) -  May 4, 2023   
    With the new definitions, there are many studies emerging to investigate the pathogenesis of sarcopenia, exploring new interventions to treat sarcopenia and evaluating the efficacy of combination treatments for sarcopenia. The scope of this chapter is to summarize and appraise the evidence in terms of (1) clinical signs, symptoms, screening, and diagnosis, (2) pathogenesis of sarcopenia with emphasis on mitochondrial dysfunction, intramuscular fat infiltration and neuromuscular junction deterioration, and (3) current treatments with regard to physical exercises and nutritional supplement.